NCT05344833 (HEME-18) is a Phase 2 clinical trial of Isatuximab in Multiple Myeloma, sponsored by University of Illinois at Chicago.

Who is sponsoring NCT05344833?

NCT05344833 is sponsored by University of Illinois at Chicago.

What drugs are being tested in NCT05344833?

Interventions in NCT05344833: Isatuximab, Lenalidomide.

What condition does NCT05344833 study?

NCT05344833 studies Multiple Myeloma.

Is NCT05344833 still recruiting?

NCT05344833 is currently recruiting now. Last updated 19 February 2026.

Last reviewed 2026-02-19 · How we verify

NCT05344833: HEME-18

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma

Recruiting now Phase 2 Last updated 19 February 2026

What this trial tests

Phase 2 trial testing Isatuximab in Multiple Myeloma in 50 participants. Currently enrolling.

Timeline

5 January 2023

Primary endpoint
1 December 2030

1 December 2030

Quick facts

Lead sponsor	University of Illinois at Chicago
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	50
Start date	5 January 2023
Primary completion	1 December 2030
Estimated completion	1 December 2030
Sites	2 locations across United States

Drugs / interventions tested

Isatuximab (isatuximab) — full drug profile →
Lenalidomide — full drug profile →

Conditions studied

Multiple Myeloma — all drugs for Multiple Myeloma →

Sponsor

University of Illinois at Chicago

Who can join

18 and older, any sex, with Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Number of participants that have MRD-negative CR rate, defined as 10-6
Time frame: 1 year
Evaluate the number of participants that have MRD-negative at 1 year that were MRD-positive multiple myeloma (MM) treated with isatuximab and lenalidomide based maintenance after ASCT

Sponsor's own description

This is a phase II study where patients will undergo isatuximab and lenalidomide maintenance if they are MRD-positive after Autologous Stem Cell Transplant (ASCT)

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The Landscape of Currently Enrolling Maintenance Trials in Multiple Myeloma.
Tariq SM, Abdallah AO, Goodman A, Sborov D, et al · · 2023 · cited 3× · PMID 37133718 · DOI 10.1007/s44228-023-00044-8

Verify or expand the search:

Other trials of Isatuximab

Trials testing the same drug.

NCT07045909 — Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST) · Phase 2 · recruiting
NCT05862766 — Isatuximab in Lung Transplant Recipients · EARLY_PHASE1 · withdrawn
NCT05922501 — Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma · Phase 2 · recruiting
NCT06182774 — Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Mu · Phase 3 · recruiting
NCT06203912 — Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma · Phase 1 · active not recruiting

Other recruiting trials for Multiple Myeloma

Currently open trials in the same condition.

NCT07200102 — Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma · Phase 1 · recruiting
NCT07340853 — CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma · Phase 1 · recruiting
NCT07454382 — A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma · Phase 2 · recruiting
NCT07266441 — A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma · Phase 2 · recruiting
NCT07258511 — A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With · Phase 3 · recruiting

Other University of Illinois at Chicago trials

Trials by the same sponsor.

NCT07498322 — Chicago Data-driven Opioid Use Disorder Screening, Engagement, Treatment and Planning System · NA · not yet recruiting
NCT07387705 — On Track for Wellness (OTW) Stepped Wedge Cluster Randomized Trial · Phase 1 · not yet recruiting
NCT07504120 — The Effect of Remotely Delivered Pilates on Physical , and Psychological Outcomes in Individuals With Multiple Sclerosis · NA · not yet recruiting
NCT07160582 — Cognitive-Motor Training for AD/ADRD Prevention · NA · not yet recruiting
NCT07498348 — Apple Watch Evaluation of Endodontics Occupational Stress · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05344833 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Illinois at Chicago
Last refreshed: 19 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05344833.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing